HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents

Symposium findings provide ‘wake-up call’ about postoperative complications, registry discrepancies

Nicholas J. Petrelli, MD, FACS

Society of Gynecologic Oncology appoints new CEO

Dana-Farber Cancer Institute names new president, CEO

Association of Community Cancer Centers names new president

ASCO names new CEO

Lewis C. Cantley, PhD, receives Wolf Prize in Medicine

The University of Texas MD Anderson Cancer Center honors faculty

Bladder cancer institute awards $500,000 worth of research grants

Pediatric Blood and Marrow Transplant Consortium presents lifetime achievement award

GW Cancer Center appoints associate director for patient-centered initiatives

Alcohol and cancer risk: What is the connection?

Cover Story

Toxicity, second cancers cause researchers to question radiation’s role in Hodgkin lymphoma

Drug Pipeline

Pancreatic Cancer Drugs in the Pipeline


Propensity matching and the GIGO principle

Derek Raghavan, MD, PhD

FDA News

FDA grants priority review to MPDL3280A for treatment of advanced, metastatic urothelial carcinoma

FDA grants orphan drug designation to WT1 cancer vaccine for malignant pleural mesothelioma

FDA grants orphan drug designation to BPX-501 for GVHD, immunodeficiency after stem cell transplants

FDA approves Kovaltry for hemophilia A

FDA approves Xalkori to treat ROS1-positive NSCLC

FDA reports increase of adverse events with Zydelig, six trials stopped

Imaging Analysis

A 57-year-old woman with an anterior mediastinal mass of unusual histology

Ajit Karakbelkar, MD; Munir Ghesani, MD FACNM

In the Journals

Neoadjuvant chemotherapy demonstrates favorable outcomes in pediatric germ cell tumors

Most patients with advanced cancer want genetic testing results

Poor OS observed in men with brain metastases from germ cell tumors

Poor, minority AYAs less likely to survive Hodgkin’s lymphoma

Imetelstat demonstrates safety, efficacy for essential thrombocythemia

Hospitalization for heart failure may predict VTE risk

HSCT may improve DFS, OS in older patients with AML

Intensive, multi-agent regimen may prolong EFS in metastatic rhabdomyosarcoma

PSA testing rates differ among urologists, PCPs

Trial availability, patient eligibility barriers to enrollment onto genomically matched trials

ASCO: Expanded genetic testing should be standard for metastatic colorectal cancer

USPSTF: Insufficient evidence exists for anemia testing, iron supplementation in pregnant women

Tumor-treating fields prolong PFS, OS in glioblastoma

Ropeginterferon alfa 2b shows promise for polycythemia vera

RAS/MAPK hyperactivation may predict worse outcomes in undifferentiated pleomorphic sarcomas

Shorter bleomycin regimen demonstrates acceptable toxicity profile in older patients with Hodgkin lymphoma

Routine CT scans after SBRT effectively detect NSCLC progression

Gemtuzumab ozogamicin response linked to CD33 expression level in pediatric AML

CYP3A7 allele predicts poor outcomes for lung and breast cancer, leukemia

Common genetic variants linked to high VTE incidence in black patients

Circulating histones may predict thrombocytopenia severity in ICU patients

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

Combination therapy may extend OS in metastatic pancreatic cancer

ED interventions reduce time to treatment of febrile neutropenia

Clonal abnormalities may serve as diagnostic tool for blood cancers

Financial burden linked to depression in cancer survivors

Meeting News Coverage

Extent of thyroid surgery often miscoded in cancer registries

‘Explosion of genomic data’ should improve treatment of cutaneous T-cell lymphoma

Physical activity does not impact mammographic density

Pembrolizumab shows early promise in repair-deficient endometrial cancer

Sonidegib offers long-term disease control in basal cell carcinoma

Updates in staging, management may benefit future of Merkel cell carcinoma treatment

Mastectomy improves survival in younger, BRCA-positive women with ovarian cancer

Experts debate role of completion lymphadenectomy for node-positive melanoma

Endometrial cancers with high microsatellite instability may benefit from immunotherapy

Ipilimumab, interferon debated as standard adjuvant therapy for high-risk disease

Hospital adherence to quality metrics may not improve colon cancer outcomes

Brain may become ‘just another organ’ in treatment of metastatic melanoma

Insulin may increase mammographic density in women with diabetes

Bone density scans underutilized after prophylactic oophorectomy

Benefits, harms of routine skin cancer screening uncertain

Multiple gene mutations may predict recurrence in malignant melanoma

Patients with head and neck cancer often resort to cost-coping strategies

Gene mutations extend PFS, OS in ovarian cancer

Oncogene expression may guide treatment, predict outcomes in head, neck cancer

Clinical trials ‘remain the priority’ for patients with uveal melanoma

Pharmacology Consult

The potential of reversal agents for target-specific oral anticoagulants

Amanda M. Morrill, PharmD, BCPS; Kristine C. Willett, PharmD, FASHP